Schwitzer seems to think so:
In today’s WSJ, the front page of the “Marketplace” section, page B1, has a story on the “blockbuster drug plavix” and a pack of new rivals on the horizon.But negative findings on two other drug studies are relegated to pages B6 and B7, deep in the paper and deeper in that section.
